Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesFree Cash FlowNet Cash FlowShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Gains from Sales and Divestitures (2021 - 2024)

Historic Gains from Sales and Divestitures for Syndax Pharmaceuticals (SNDX) over the last 4 years, with Q4 2024 value amounting to $85495.0.

  • Syndax Pharmaceuticals' Gains from Sales and Divestitures rose 83929.91% to $85495.0 in Q4 2024 from the same period last year, while for Dec 2024 it was $85495.0, marking a year-over-year increase of 83929.91%. This contributed to the annual value of $85495.0 for FY2024, which is 83929.91% up from last year.
  • Syndax Pharmaceuticals' Gains from Sales and Divestitures amounted to $85495.0 in Q4 2024, which was up 83929.91% from $9102.0 recorded in Q4 2023.
  • Syndax Pharmaceuticals' Gains from Sales and Divestitures' 5-year high stood at $85495.0 during Q4 2024, with a 5-year trough of $3750.0 in Q1 2022.
  • Over the past 4 years, Syndax Pharmaceuticals' median Gains from Sales and Divestitures value was $7852.0 (recorded in 2023), while the average stood at $20455.1.
  • In the last 5 years, Syndax Pharmaceuticals' Gains from Sales and Divestitures plummeted by 7651.1% in 2023 and then surged by 83929.91% in 2024.
  • Quarter analysis of 4 years shows Syndax Pharmaceuticals' Gains from Sales and Divestitures stood at $5500.0 in 2021, then soared by 604.55% to $38750.0 in 2022, then crashed by 76.51% to $9102.0 in 2023, then skyrocketed by 839.3% to $85495.0 in 2024.
  • Its Gains from Sales and Divestitures stands at $85495.0 for Q4 2024, versus $9102.0 for Q4 2023 and $9102.0 for Q3 2023.